Inflammatory but not apoptotic death of granulocytes citrullinates fibrinogen by unknown
RESEARCH ARTICLE Open Access
Inflammatory but not apoptotic death of
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Abstract
Background: Neutrophil activation induces citrullination of intracellular targets of anticitrullinated peptide
antibodies (ACPA), which are specific for rheumatoid arthritis (RA). Citrullinated fibrinogen is bound by ACPA but it
is less well understood how extracellular proteins are citrullinated. The cells that produce fibrinogen, hepatocytes,
do not express peptidyl arginine deiminase (PAD) enzymes nor do PAD enzymes include N-terminal signal peptides
to direct them into the secretory pathway. We hypothesized that dying neutrophils release PAD in the extracellular
space, and that this could cause citrullination of target extracellular antigens relevant to RA such as fibrinogen.
Methods: HL60 cells were differentiated into neutrophil-like cells by treatment with all-trans retinoic acid (ATRA).
Differentiation was confirmed by CD11b staining, PAD4, PAD2 and myeloperoxidase expression, cell division, and
nuclear morphology. Death was induced with various stimuli, including freeze-thaw to induce necrosis, Ionomycin and
PMA to induce NETosis, and UV-B to induce apoptosis. Death markers were assessed by immunohistochemistry and
flow cytometry. To quantify extracellular citrullination, dying ATRA-differentiated HL60 cells were cultured with
fibrinogen for 24 hours and supernatants were probed for fibrinogen citrullination, PAD2 and PAD4 by western blot.
Results: While both NETotic and necrotic ATRA differentiated HL60 cells citrullinated fibrinogen, apoptotic cells did not
citrullinate fibrinogen, even when allowed to undergo secondary necrosis. Incubation of necrotic neutrophil lysates with
fibrinogen also causes fibrinogen citrullination. PAD2 and PAD4 were detected by western blot of supernatants of ATRA-
differentiated HL60 cells undergoing necrotic and NETotic death, but not apoptotic or secondarily necrotic cell death.
Conclusion: We implicate granulocytes undergoing inflammatory cell death as a mechanism for altering extracellular
self-proteins that may be targets of autoimmunity linked to inflammatory diseases such as rheumatoid arthritis.
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Background
The majority of patients with rheumatoid arthritis (RA)
harbor anticitrullinated peptide antibodies (ACPA), which
are markers of disease severity. ACPA bind citrullinated
isoforms of numerous intracellular antigens including
vimentin and alpha enolase. Recent work has identified
hypercitrullination of multiple intracellular neutrophil an-
tigens after exposure to pore forming stimuli such as
Ionomycin, complement and granzyme B [1] and on neu-
trophil extracellular traps (NETs) [2].
In addition to targeting intracellular citrullinated anti-
gens, ACPA also bind citrullinated isoforms of various
extracellular antigens. One such citrullinated extracellu-
lar antigen recognized by ACPA is citrullinated fibrino-
gen. Autoantibodies to citrullinated fibrinogen are 98 %
specific for RA [3] and proteomic studies of synovial tis-
sue and fluid have identified citrullinated fibrinogen as
one of the major sources of citrullinated antigen in the
joints in RA [4–6]. It is not known how extracellular
proteins such as fibrinogen are citrullinated because the
cells that produce fibrinogen, hepatocytes, do not ex-
press any of the peptidylarginine deiminase (PAD) family
of enzymes nor do any of the PAD enzymes include N-
terminal signal peptides that would direct them into the
secretory pathway [7]. PAD4 is required for histone 3
(H3) citrullination and NETosis and recent work has
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shown that PAD4 may also be extruded on NETs [8].
Synovial fluid from patients with RA citrullinates fi-
brinogen in vitro, suggesting PAD enzymes in RA are
externalized in the synovial fluid [9]. Though both PAD2
and PAD4 citrullinate fibrinogen [9], it remains unclear
under which conditions PAD enzymes function in the
extracellular compartment and whether PAD4 enmeshed
in NET DNA retains enzymatic activity. A better under-
standing of the mechanisms by which fibrinogen can be-
come citrullinated in the context of inflammation would
facilitate dissection of the immune pathways that lead to
autoreactivity to citrullinated extracellular antigens.
We hypothesized that dying neutrophils release PAD en-
zymes that remain functional in the extracellular compart-
ment, and that this release could cause citrullination of
target antigens relevant to RA such as fibrinogen. We
therefore compared citrullination of fibrinogen cultured
with granulocytes undergoing various types of cell death
and discovered that apoptotic cells do not citrullinate fi-
brinogen, even when allowed to undergo secondary necro-
sis, but both NETotic and necrotic granulocytes citrullinate
fibrinogen in culture. We therefore implicate neutrophils
undergoing inflammatory cell death as a mechanism for al-
tering extracellular self-proteins that may be targets of
autoimmunity linked to inflammatory diseases such as RA.
Methods
Differentiating HL60 cells
HL60 cells were obtained from ATCC (Manassas, VA
#CCL-240) and maintained in RPMI 1640 media (Invitrogen,
Grand Island, NY, USA) supplemented with 20 % fetal
bovine serum (FBS), 2 mM L-glutamine, 25 mM hydox-
yethyl piperazineethanesulfonic acid (HEPES, Invitrogen),
non-essential amino acid (Invitrogen), sodium pyruvate
(Cellgro, Manassas, VA, USA) and gentamycin (Invitrogen).
Cells were maintained at a density of 1 × 105 to 5 × 105
cells/ml for a maximum of 30 passages. Cells were treated
with varying concentrations of all-trans retinoic acid
(ATRA) (Sigma, St. Louis, MO, USA) dissolved in dimethyl
sulfoxide (DMSO) (Sigma-Aldrich) for varying amounts of
time as described in the text.
RT-qPCR
mRNA was isolated from HL60 and ATRA HL60 with
Trizol (Invitrogen) and High Pure RNA Isolation kit
(Roche Diagnostics, Mannheim Germany), cDNA was
synthesized with iScript (BioRad, Hercules, CA, USA).
Primer pair sequences were: PADI4 forward: GCACAA
CATGGACTTCTACGTGG, reverse: CACGCTGTCTT
GGAACACCACA; HRP14 forward: CGGAGCTGACCA
GACTTTTC, reverse: GGTTCGACCGTCATACTTCT




curve analysis) and priming efficiency (standard curve)
was confirmed. BioRad CFX96 system and FastStart SYBR
Green Master (Roche) were used for real-time PCR.
Microscopy
Cells were seeded onto polylysine-D coated culture slides
(Corning, Tewksbury, MA, USA), incubated at 37 °C for
30 minutes, fixed with 4 % paraformaldehyde at room
temperature for 15 minutes, and permeablized with PBS
containing 0.1 % Triton-X100 (Sigma-Aldrich). Cells were
stained with 4,6-diamidino-2-phenylindole (DAPI) (Sigma-
Aldrich) and images were obtained with an Axioplan 2
microscope (Zeiss, Oberkochen, Germany).
Flow cytometry
First, 105–106 cells were stained with CD11b-FITC (BD
Pharmingen, San Jose, CA, USA) in staining buffer (PBS
with 1 % pooled human serum and 1 % FBS), washed
and resuspended in AnnexinV-staining buffer (Molecular
Probes, Thermo Fisher, Waltham Massachusetts) with
AnnexinV-FITC (BD Pharmingen) for 15 minutes, 37 °C.
Prior to analysis, cells were treated with 100 nM of cell
impermeant nucleic acid stain (TOPRO-3 iodide)
(Invitrogen).
Ionomycin and PMA treatment
ATRA/HL60 were resuspended at 5 × 106/ml in media
(Hanks balanced salt solution (HBSS)) supplemented with
5 mM CaCl2, 5 mM DL-Dithiothreitol (DTT) (Sigma-
Aldrich), 0.25 mM HEPES (Invitrogen) and where indi-
cated, 1 mg/ml fibrinogen (Sigma-Aldrich) and cultured
with 100 nM Ionomycin (Sigma-Aldrich) or 100 nM phor-
bol 12-myristate 13-acetate (PMA) (Sigma-Aldrich).
UV irradiation
ATRA/HL60 were plated at 1 × 106/ml in media (HBSS
supplemented with 2–5 mM CaCl2, 5 mM DL-
Dithiothreitol (DTT) (Sigma-Aldrich), 0.25 mM HEPES
(Invitrogen) and where indicated, 1 mg/ml fibrinogen
(Sigma-Aldrich), treated with 120 mJ/cm2 of UV-B
irradiation and incubated at 37 °C for various durations.
Freeze thaw
ATRA/HL60 were resuspended at 5 × 106/ml in media
(HBSS supplemented with 2–5 mM HEPES (Invitrogen)
and where indicated, 1 mg/ml fibrinogen (Sigma-Aldrich)
and treated with four4 cycles of alternating dry ice and
quick thaw in a 37 °C water bath.
Staurosporine treatment
ATRA/HL60 cells were resuspended at 5 × 106/ml in
media (HBSS supplemented with 2 mM CaCl2, 5 mM
DTT (Sigma-Aldrich), 0.25 mM HEPES (Invitrogen) and
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where indicated, 100 ug of fibrinogen (Sigma-Aldrich)
and treated with 1 uM staurosporine (Sigma-Aldrich).
Western blots
ATRA/HL60 treated with various death-inducing stimuli as
above, were incubated overnight at 37 °C. Supernatant was
transferred to an eppendorf tube, centrifuged at 2,000 rpm
for 2 minutes at room temperature, resuspended in 4 ×
sample buffer, boiled for 5 minutes, and centrifuged again
at 14,000 rpm for 5 minutes. Then 25 ul were resolved by
polyacrylamide gel electrophoresis and transferred to poly-
vinylidene fluoride (PVDF) membranes (Millipore). The
membranes were blocked in 5 % non-fat milk in Tris-
buffered saline (TBS) containing 0.1 % Tween 20, for 1 hour
at room temperature. Membranes were probed with anti-
bodies: monoclonal anti-citrullinated fibrinogen (Cayman
Chemical, Ann Arbor, MI, USA), monoclonal anti-PAD2
antibody [10] (Abnova, #H00011240-M01, Taipei City,
Taiwan), anti-PAD4 antibody [11] (Abcam #ab128086,
Cambridge, MA, USA), monoclonal anti-fibrinogen
(Abcam #ab10066), anti-citrullinated H3 (Abcam
#ab5103), anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Life Technologies #AM4300, Grand Island, NY,
USA) and bound immunoglobulin was detected with
horseradish peroxidase-linked secondary antibodies (Life
Technologies). Reactivity was visualized with an ECL (en-
hanced chemilluminescence) substrate (Western Lightning®
Plus-ECL, Perkin Elmer, Waltham Massachusetts) system.
Peripheral blood neutrophils (PMN) western blot
In accordance with the Institutional Review Board
reviewed protocol (RUH DOR0722), PMN were isolated
using a Ficoll-paque plus (GE Healthcare, Pittsburgh,
PA, USA) density gradient followed by hypotonic lysis.
Cells (1 × 106) were subjected to four cycles of freeze
thaw in 200 ul of media (HBSS supplemented with
10 mM CaCl2, 5 mM DTT (Sigma-Aldrich), 0.25 mM
HEPES (Invitrogen) and 100 ug of fibrinogen (Sigma-
Aldrich) and incubated for various durations. Soluble
fractions were harvested, resolved and probed as above.
Results
ATRA differentiates HL60 into neutrophil-like cells
Because a significant percentage of primary neutrophils
undergo spontaneous apoptosis and necrosis over time in
response to basic in vitro manipulation, we used the acute
promyelocytic leukemia cell line, HL60 cells, to more
easily control cell death in culture. We first sought to
confirm that the treatment of HL60 cells with ATRA
terminally differentiates them to become neutrophil-like
in culture. HL60 were treated with varying concentrations
of ATRA or left untreated. Survival and CD11b expression
were measured 3 days later. ATRA-treated HL60 cells
upregulated CD11b in a dose-dependent manner.
They become apoptotic when exposed to very high con-
centrations (125 uM) of ATRA (Fig. 1a). Consistent with
differentiation to a more mature phenotype, ATRA-
treated HL60 upregulated expression of PAD4 and PAD2
mRNA, while they downregulated expression of myelo-
peroxidase mRNA (Fig. 1b). Because 25 uM ATRA led to
the highest CD11b expression without inducing apoptosis,
this concentration was used for future experiments to
induce differentiation. Growth curves confirmed that
4 days of ATRA treatment caused HL60 cells to stop div-
iding (Fig. 1c) and their nuclear morphology to become
multi-lobar (Fig. 1d). Taken together, these data confirmed
that ATRA treatment differentiated HL60 cells (ATRA/
HL60) into a neutrophil-like cell, with increased expres-
sion of PAD2 and PAD4 and cell surface expression of
CD11b.
ATRA/HL60 cells treated with Ionomycin, PMA and UV-B
undergo distinct forms of cell death
We next sought to generate different types of cell death in
ATRA/HL60. Cells were treated with Ionomycin, PMA or
UV-B irradiation and nuclear morphology was evaluated
by DAPI staining. Ionomycin and PMA-treated cells de-
veloped nuclear morphology consistent with NETosis,
while UV-irradiated cells were characterized by nuclear
blebs consistent with apoptosis (Fig. 2a). A limitation of
assessing death by nuclear morphology is that it is difficult
to definitively distinguish between NETosis and necrosis.
NETosis is associated with increased citrullination of H3.
Western blots of Ionomycin-treated cell lysates demon-
strated increased citrullinated H3 relative to unstimulated
cells (Fig. 2b), consistent with the NETotic nuclear
morphology seen in Fig. 2a. PMA and Ionomycin treat-
ment induced the same amount of citrullination of histone
H3 at 2 hours (Additional file 1), but at 6 hours, the result
for PMA treatment was no different to that for unstimu-
lated cells, consistent with a prior report [12].
To better quantitate the extent of necrosis and apoptosis
in the various conditions, we compared Annexin V and
TOPRO labeling at several time points (Fig. 2c). Each
stimulus led to a mix of various types of cell death. Iono-
mycin treatment led to death of 57 % of the cells in
2 hours. Ionomycin induced death was largely character-
ized by breakdown of cell membrane integrity (TOPRO+)
and progressed to involve 92 % of cells at 24 hours. PMA
induced death in 45 % of the cells at 2 hours, however, this
was characterized by two distinct populations, TOPRO+
and TOPRO–/Annexin V+ cells. Interestingly, 43 % of cells
still excluded TOPRO after 24 hours of PMA treatment.
UV irradiation predominantly produced a population of
apoptotic cells (Annexin V+/TOPRO–) at 2 hours, which
largely became secondarily necrotic at 24 hours
(Additional file 2). Taken together, these results demon-
strate that UV irradiation induces apoptosis and ultimately
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secondary necrosis while Ionomycin treatment induces
NETosis and necrosis and PMA treatment induces a mix
of various types of cell death including NETosis and
apoptosis.
Inflammatory, but not apoptotic, granulocyte death leads
to citrullination of fibrinogen
We reasoned that granulocytes undergoing cell death
could release functional PAD enzymes into their local
environment and that these could function to citrullinate
extracellular fibrinogen. To test this hypothesis, ATRA/
HL60 cells were cultured with fibrinogen while treated
with stimuli that induce different types of cell death and
fibrinogen citrullination in culture supernatants was
assessed by western blot. ATRA/HL60 cells treated with
Ionomycin, PMA or four cycles of freeze thaw (to induce
primary necrosis) induced strong citrullination of fi-
brinogen while apoptotic ATRA/HL60 cells treated with
UV did not. This finding persisted even after 24 hours in
culture allowing for secondary necrosis and loss of
membrane integrity of the UV-irradiated apoptotic cells
(Fig. 3a). Blots were stripped and reprobed with anti-
fibrinogen antibody to ensure that any negative signals
were not due to degradation of fibrinogen itself by
ATRA/HL60 proteases. The amount of total fibrinogen
did not change in any culture group. Freeze thawed
(necrotic) ATRA/HL60 lysates incubated for 24 hours
without fibrinogen did not cause citrullination (Fig. 3b),




























































Fig. 1 Trans retinoic acid (ATRA) differentiates HL60 acute promyelocytic cell line to neutrophil-like cells. a CD11b and Annexin V staining of HL60
cells treated with various concentrations of ATRA for 3 days. b qPCR of HL60 cells treated with various concentrations of ATRA for 3 days. Data
are mean fold-induction of mRNA normalized to untreated HL60 cells (scored as 1) + SD of triplicate wells. c Growth curve of cultured HL60 cells
or ATRA-treated HL60 cells over time. Cells were plated at a density of 1 × 105/ml and split when the concentration exceeded 5 × 105/ml. Data
are mean cell counts +/− SD of triplicate culture plates (d) 4,6-diamidino-2-phenylindole staining of nuclear morphology of ATRA-treated or
untreated HL60 cells. All data are representative of three independent experiments. PAD peptidylarginine deiminase
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To confirm that apoptotic cells do not lead to fibrino-
gen citrullination and that our observation was not
unique to UV-irradiated cells only, we also tested
whether ATRA/HL60 cells undergoing apoptosis sec-
ondary to staurosporine treatment [13] induced fibrino-
gen citrullination. Though staurosporine treatment
induced apoptosis more slowly than UV irradiation,
37 % of cells were apoptotic at 4 hours and 76 % of cells
were secondarily necrotic by 24 hours. Staurosporine
treated ATRA/HL60 cells did not lead to citrullination
of fibrinogen after 24 hours of culture (Fig. 3b). We also
tested whether necrotic human blood-derived neutro-
phils citrullinated extracellular fibrinogen and found that
they induced very rapid citrullination after only 5 mi-
nutes of incubation (Fig. 3c), and that freeze thawed
neutrophils alone without incubation with supplemental
fibrinogen did not contain citrullinated fibrinogen.
Western blots of live unstimulated ATRA/HL60 cell pel-
lets demonstrated binding by anti-PAD2 (Fig. 3d) and
anti-PAD4 antibodies (Fig. 3e) and after incubating cell
lysates for 24 hours, a broad range of bands between 76
and 24 kD were detected by anti-PAD2 antibody and a
distinct band was detected at 31 kD by the anti-PAD4
antibody. It is likely that these additional bands repre-
sent PAD degradation products.
A potential interpretation of the finding that ATRA/
HL60 cells citrullinate fibrinogen specifically when
undergoing inflammatory but not apoptotic death is that
apoptotic death effectively sequesters PAD enzymes and
deactivates them before they can access the extracellular
compartment to citrullinate other neighboring proteins
even if allowed to undergo secondary necrosis. To dir-
ectly test this hypothesis, we measured PAD2 and PAD4
in the supernatants of dying ATRA/HL60 cells. Superna-
tants of freeze thawed PMA- and Ionomycin-treated
cells were bound by a monoclonal anti-PAD2 antibody
at the PAD2 predicted molecular weight of 76 Kd, and
additional bands, which likely represent degradation
products. In contrast, supernatants of UV-irradiated cells
were not bound with the anti-PAD2 antibody (Fig. 3f ).
Supernatants of freeze thawed cells demonstrated a faint
band stained by a monoclonal antibody to PAD4 at 74
kD, the predicted molecular weight of PAD4, with a
stronger band at 31 kD in the freeze thaw, PMA and
Ionomycin groups, which is likely to be a PAD4 degrad-
ation product (Fig. 3g). Anti-PAD4 antibody did not

































Fig. 2 Ionomycin, phorbol 12-myristate 13-acetate (PMA) and UV-B induce distinct forms of granulocyte cell death. a Trans retinoic acid (ATRA)-
differentiated HL60 cells treated with no stimulation, Ionomycin, PMA, or UV-B and stained with 4,6-diamidino-2-phenylindole. b Unstimulated
(NO STIM) and Ionomycin-treated (IONO) granulocytes screened by western blot for citrullination of H3. Blots were stripped and reprobed for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a load control. c Flow cytometry (ungated) of ATRA-differentiated HL60 cells treated with
Ionomycin, PMA or UV-B and stained with Annexin V and cell impermeant nucleic acid stain (TOPRO). Data are representative of at least three
independent experiments
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bind supernatants of UV-irradiated cells. These results
indicate that ATRA/HL60 cells undergoing inflamma-
tory cell death, but not apoptotic death, release PAD2
and PAD4, and this correlates with citrullination of fi-
brinogen in the extracellular compartment.
Discussion
Bone marrow precursors produce approximately 50 billion
neutrophils per day. In order to maintain homeostasis,
neutrophils undergo apoptosis spontaneously after 5 days
in circulation and 1–2 days after trafficking to tissue.
Inflammatory stimuli known to be risk factors for RA,
such as periodontal infection or cigarette smoke, can lead
to alternate types of neutrophil death including NETosis,
autophagy and necrosis [14]. Dead or dying neutrophils
can in turn directly alter immune responses positively or
negatively depending on the inflammatory milieu, and the
type of neutrophil death [15]. Modeling neutrophils using
a differentiated promyelocytic leukemia cell line (HL60),
we describe how inflammatory neutrophil death can lead
to modification of extracellular proteins such as fibrino-































































































































































































































































































Fig. 3 Inflammatory, but not apoptotic, granulocyte death leads to citrullination of fibrinogen. a Western blot of supernatants of trans retinoic
acid (ATRA)/HL60 cells treated with indicated death-inducing stimuli and cultured in Hanks balanced salt solution (HBSS)/fibrinogen/5 mM calcium for
24 hours. Purified citrullinated fibrinogen and fibrinogen (without added ATRA/HL60 cells) were run as positive and negative controls, respectively.
These lanes were not adjacent on the original gel. Blots were stripped and reprobed with anti-fibrinogen antibody as a load control. b Western blot of
supernatants of ATRA/HL60 cells treated with indicated death-inducing stimuli and incubated in HBSS with or without fibrinogen and 2 mM calcium
for 24 hours. c Western blot of primary human neutrophil lysate incubated with fibrinogen/calcium for indicated times. Peripheral blood neutrophils
(PMN) alone (PMN alone) neutrophil lysate without fibrinogen, was not adjacent on the original gel. Western blots of time (T) = 0 ATRA/HL60 cell pellet
or soluble fraction of ATRA/HL60 cells treated with four cycles of freeze thaw and then incubated for 24 hours and probed with anti-peptidylarginine
deiminase (PAD)2 antibody (d) or anti-PAD4 antibody (e). f Western blot of soluble fraction of ATRA/HL60 cells treated with indicated death-inducing
stimuli and cultured in HBSS/fibrinogen/5 m M calcium for 24 hours and probed with anti-PAD2 antibody (f) or anti-PAD4 antibody (g). PMA phorbol
12-myristate 13-acetate, IONO Ionomycin, GAPDH glyceraldehyde-3-phosphate dehydrogenase
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As ATRA-differentiated cells express high levels of
PAD2 and PAD4, it is reasonable to propose that dying
cells could release these enzymes and that they could
continue to be functional, particularly as the calcium
levels in the extracellular space are higher relative to the
intracellular compartment. A limitation of this work is
that it is not possible to distinguish whether PAD2 or
PAD4 was responsible for citrullination of fibrinogen in
our assay, because they were both detectable in the cell
media supernatants. It is worth noting that PAD4 was
detected at a lower molecular weight than expected (31
kD) and this may have represented a non-functional
degradation product, while PAD2 remained detectable at
its predicted molecular weight of 76 kD. Additionally, it
was not possible to induce NETosis without inducing
concurrent necrosis and therefore, we cannot discern
whether NETosis is required for extracellular citrullina-
tion. Freeze thaw, which induces only necrosis, was suf-
ficient, however, to induce fibrinogen citrullination.
Perhaps the more surprising finding is that apoptotic
and even secondarily necrotic cells did not citrullinate
extracellular fibrinogen in culture. This result indicates
that death by apoptosis deactivates the PAD enzymes be-
fore they are released into the extracellular space and is
consistent with prior work demonstrating that PAD4-
mediated histone deimination is induced by inflam-
matory stimuli in neutrophils but not apoptosis [16].
Considering the vast numbers of neutrophils that
undergo apoptosis daily, it stands to reason that this im-
munologically silent cell death would also have evolved
mechanisms to limit modifications of neighboring pro-
teins. Single nucleotide polymorphisms in PADI4 and
PADI2 are associated with increased risk of RA. PADI4
risk alleles reside in the N-terminal domain, which is not
the catalytic site of enzyme activity, and these risk alleles
do not lead to enzymes that are hyperfunctional in vitro,
leading to the hypothesis that the polymorphism may
confer risk by increasing either protein or mRNA stabil-
ity rather than increased protein function [11]. The work
presented here supports the notion that increased PAD
stability could contribute to RA risk by demonstrating
that PAD enzymes released in the setting of certain
types of cell death continue to function in the extra-
cellular space.
While autoantibodies to citrullinated fibrinogen are
highly specific to RA, citrullination of fibrinogen is not.
Non-RA patient-derived atherosclerotic plaques contain
both citrullinated fibrinogen and PAD4 [17]. As neutro-
phils express more PAD4 than any other hematopoietic
cells, this result suggests that neutrophils may be re-
sponsible for fibrinogen citrullination in vivo. Further,
neutrophil-derived serine proteases promote coagulation
and thrombosis formation in vitro and in vivo [18] and
known products of NETosis, such as DNA, MPO and
citrullinated H3, can be detected in organized human
thrombus [19]. The work presented here provides a dir-
ect link between the observations of the importance of
neutrophils in thrombus organization and the observa-
tion that thrombus contains citrullinated fibrinogen.
Conclusions
In conclusion, we found that granulocytes undergoing in-
flammatory but not apoptotic cell death lead to citrullina-
tion of the extracellular protein, fibrinogen. Fibrinogen
citrullination correlates with detectable levels of PAD en-
zymes in the supernatant of granulocytes undergoing in-
flammatory but not apoptotic cell death. This work
provides a direct link between previous observations on
the role of neutrophils in thrombosis and citrullination of
fibrinogen, and points yet another finger at neutrophils in
the generation of post-translational modifications targeted
by RA autoantibodies.
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Additional file 1: Western blot of trans retinoic acid (ATRA)/HL60 at
various time points probed with anti-citrullinated histone H3. NO STIM
no stimulation, PMA phorbol 12-myristate 13-acetate, IONO ionomycin.
(PDF 199 kb)
Additional file 2: FACS staining of trans retinoic acid (ATRA)/HL60
cells treated with staurosporine. T time, TOPRO cell impermeant
nucleic acid stain. (PDF 199 kb)
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